4 news items
Genetics in Medicine Publishes Myriad Genetics Patient-Outcomes Study Validating RiskScoreĀ® as a Clinical Breast Cancer Risk Assessment Tool
MYGN
3 Jun 24
use of RiskScore may therefore lead to more accurate identification of women who may benefit from enhanced breast cancer surveillance strategies
QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications
MYGN
QGEN
30 May 24
patients who are most likely to benefit from targeted treatments, such as LYNPARZA® (olaparib) by AstraZeneca. "Our
Myriad Genetics Study Published In JCO Precision Oncology Shows Co's Prolaris Test Can Predict Benefit Of Hormone Therapy Treatment In Men With Localized Prostate Cancer
MYGN
16 May 24
Myriad's Prolaris Test is the only biomarker test to quantify the benefits of adding androgen deprivation therapy to radiation therapy1SALT
New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer
MYGN
16 May 24
biomarker test to quantify the benefits of adding androgen deprivation therapy to radiation therapy1 SALT LAKE CITY, May 16
- Prev
- 1
- Next